These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Use of insulin sensitizers in NASH. Khashab M; Chalasani N Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937 [TBL] [Abstract][Full Text] [Related]
9. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? Musso G; Anty R; Petta S Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094 [TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for non-alcoholic steatohepatitis. Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366 [TBL] [Abstract][Full Text] [Related]
17. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
18. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142 [TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. Tang JT; Mao YM J Dig Dis; 2017 Nov; 18(11):607-617. PubMed ID: 29106066 [TBL] [Abstract][Full Text] [Related]
20. The role of medications for the management of patients with NAFLD. Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]